文献速递乳腺癌妇科肿瘤

BRCA携带者预防性输卵管卵巢切除后激素替代治疗与乳腺癌风险

Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
PubMed 文献 · Eur J Cancer · 2021-03-17

该回顾性队列纳入306例接受预防性输卵管卵巢切除(RRSO)的健康BRCA1/2携带者,平均随访7.26年。HRT组乳腺癌发生率为13.5%(20/148),非HRT组为10.3%(16/155),OR=1.4(95%CI 0.7-2.7)。RRSO时年龄>45岁者HRT使用者乳腺癌风险显著升高(OR=3.43,95%CI 1.2-9.8,p<0.05),≤45岁者未见影响。

要点

  • RRSO后短期HRT整体未显著增加BRCA携带者乳腺癌风险。
  • RRSO时年龄>45岁者使用HRT与约三倍乳腺癌风险相关。
  • RRSO时年龄≤45岁者HRT未见对乳腺癌发生率的影响。

核心结论

  • 在BRCA1/2携带者中,RRSO后短期HRT使用在年龄>45岁者中与约三倍乳腺癌风险相关,风险可能与接近自然绝经年龄的HRT暴露时间有关。

研究设计与样本

  • 回顾性队列研究,纳入306例连续的健康BRCA1/2突变携带者,均已行RRSO,平均随访7.26年,比较接受与未接受HRT者的乳腺癌发生率。

主要发现

  • RRSO时年龄≤45岁者,HRT未影响乳腺癌发生率。
  • RRSO时年龄>45岁者,HRT使用者乳腺癌发生率显著高于非使用者(OR=3.43,95%CI 1.2-9.8,p<0.05)。

关键数值与推荐

  • 一般人群中HRT使用者乳腺癌风险升高(风险比=1.34),为本研究背景参照。
  • RRSO时年龄>45岁者HRT与乳腺癌风险OR=3.43(95%CI 1.2-9.8,p<0.05)。
  • RRSO时年龄≤45岁者HRT对乳腺癌发生率未见影响。

临床怎么用

  • 对RRSO后需HRT的BRCA1/2携带者,应结合RRSO时年龄评估乳腺癌风险,>45岁者需谨慎权衡HRT获益与风险。

局限性

  • 为回顾性队列研究,样本量有限,HRT总体比较的95%CI跨越1,结果需进一步研究验证以指导推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: BRCA1/BRCA2 mutation carriers often undergo risk-reducing salpingo-oophorectomy (RRSO) before natural menopause, raising the issue of hormonal replacement treatment (HRT) use. There is conflicting evidence on the effect of HRT on breast cancer (BC) risk, and there are limited data on risk based on age at exposure. In the general population, HRT users have an increased BC risk (hazard ratio = 1.34). We assessed the impact of short-term HRT use on BC risk among healthy BRCA1/2 mutation carriers, with emphasis on age at exposure to HRT. METHODS: A retrospective cohort of 306 consecutive healthy BRCA1/2 mutation carriers who had undergone RRSO was followed up for a mean of 7.26 years. We compared BC incidence over time in carriers who received HRT with that in those who did not receive. RESULTS: Thirty-six of the carriers were diagnosed with BC, 20 of 148 patients (13.5%) in the HRT group compared with 16 of 155 (10.3%) in the non-HRT group (odds ratio [OR] = 1.4, 95% confidence interval [CI] = 0.7-2.7). In women who were aged 45 years or younger at RRSO, HRT did not affect BC rates. However, in those older than 45 years at RRSO, BC rates were significantly higher in HRT users than in non-users (OR = 3.43, p < 0.05, 95% CI = 1.2-9.8). CONCLUSIONS: In BRCA1/BRCA2 carriers in this study, short-term post-RRSO HRT use was associated with a threefold risk of BC in carriers older than 45 years. These results suggest that risk may be related to time of exposure to HRT around the natural age of menopause, even among BRCA1/2 carriers. Further studies are needed for validation and to guide future recommendations.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Michaelson-Cohen R, Gabizon-Peretz S, Armon S, et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer. 2021. PMID: 33743487. doi:10.1016/j.ejca.2021.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。